The Russian group of companies R-Pharm has agreed with AstraZeneca on the production of a vaccine against COVID-19, Alexey Repik, chairman of the board of directors of R-Pharm, said on the air of the state channel Russia-24 in July.
At the same time, the suspension of trials clearly showed the fallacy of the approach, when entire countries exclusively rely on novel and untested platforms when choosing a vaccine. Moderna is now conducting phase III trials across the United States and has recruited 30,000 healthy people who are being administered the shots of this vaccine. But according to the expert, the vaccine will get ready by early next year by stated, "We're not going to beat the second wave now".
The researchers flagged concerns over seemingly identical levels of antibodies in a number of study participants who were inoculated with the experimental vaccine.
The statement came in response to AstraZeneca's announcement that vaccine trials have resumed in the UK. Earlier this month, respected British medical journal The Lancet confirmed that the vaccine was 100 percent effective and caused no serious adverse effects, but stressed the need for further long-term trials.
Emergency authorisation of the vaccine is also on the cards, indicated the minister during an interaction with his social media followers, "Jan Samvad", on Sunday. Sir John Bell, who is Oxford University's regius professor of medicine claims that the majority of the vaccines take nearly eight years to develop while the research into the novel coronavirus has only been going for eight months.
The ongoing Phase 3 Oxford COVID-19 vaccine trial spans five continents: the United States, Brazil, South Africa, the UK and India.
Over 18,000 individuals globally have reportedly received study vaccines as part of the trial.
AstraZeneca's vaccine uses a monkey adenovirus that shares a gene with the Covid-19 coronavirus - a platform that hasn't been subjected to any long-term studies.
Volunteers take a PCR test to make sure they have not been infected with the virus, Health Ministry spokesman Khaled Megahed said in the statement. After this, on September 9, Serum also stopped his trial after DCGI's objection.
The CoronaVac is a vaccine which is being developed and produced by a private Chinese firm, SinoVac Biotech. The trials have been halted after the Drugs Controller General of India sought data on the safety profile of the vaccine because of an unexplained illness in a volunteer in the UK.